There is notable controversy about the role of psychotherapy in clinical trials of psychedelic-assisted therapy (PAT). This heated and perpetually evolving debate informs questions such as how much therapy should accompany a psychedelic intervention (Marseille et al., 2022), what type of therapy most effectively complements psychedelic administration (Cavarr...
= 7) in an open-label trial investigating PAT for cancer-related demoralization and chronic pain. Patients and caregivers were interviewed after their last treatment session in the trial; facilitators were interviewed at the end of the entire trial. Rapid qualitative analysis identified specific domains for improvement in the treatment protocol based on the ...
Psychedelic medicine has existed for thousands of years as a traditional, sacred practice and is now in varying stages of legalization for clinical application in the United States. PsychedelicAssisted Therapy uses specific psychoactive substances to facilitate altered states of consciousness in which clients have access to unconscious material and there is ...
Chronic stress exerts profound effects on mental health, contributing to disorders such as depression, anxiety, and cognitive impairment. This study examines the potential of psilocybin to alleviate behavioral despair and cognitive deficits in a rodent model of chronic stress, focusing on the interplay between the Hypothalamic-Pituitary-Adrenal (HPA) axis an...
Importance: The psychological morbidity experienced by physicians, advanced practice practitioners (APPs), and nurses from working during the COVID-19 pandemic includes burnout, depression, and posttraumatic stress disorder (PTSD). Objective: To investigate whether psilocybin therapy could improve symptoms of depression, burnout, and PTSD in US clinicians wh...
Key Clinical Message: This case study describes the feasibility and safety of psychedelic-assisted therapy (PAT) as a home-based intervention for a patient with throat cancer experiencing significant existential distress. The patient tolerated the intervention well. This case supports the feasibility and safety of PAT for patients with life-threatening condi...
Several phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsychiatric conditions, including major depressive disorder (MDD). However, the mechanisms underlying its often persisting beneficial effects remain unclear. Observational research suggests that improvements in psychological flexi...
We examined if the therapeutic alliance between study participants and intervention facilitators in a psilocybin-assisted therapy (PAT) trial changed over time and whether there were relationships between alliance, acute psilocybin experiences, and depression outcomes. In a randomized, waiting list-controlled clinical trial for major depressive disorder in a...
Psychedelic substances induce profound alterations in consciousness. Careful preparation is therefore essential to limit adverse reactions, enhance therapeutic benefits, and maintain user safety. This paper describes the development of a self-directed, digital intervention for psychedelic preparation. Drawing on elements from the UK Medical Research Council ...
Abstract Background and aims Psychedelic-assisted therapy (P-AT) has been shown to reduce post-traumatic stress disorder (PTSD), depression, and anxiety symptoms, and is likely to be approved in the United States (US) in the coming years. However, concerns about participant safety in these early trials have surfaced, including allegations of sexual misconduc...
Abstract Objective: Psychedelic-assisted therapies are emerging as safe and effective treatments for some psychological conditions including depression, anxiety, posttraumatic stress disorder, and substance use disorders. As ketamine therapy is already available in general medicine and 3,4 Methylenedioxymethamphetamine (MDMA) and psilocybin are in late-stage...
This review presents a general background of psilocybin pharmacology and discusses its uses in treating various mental health disorders such as depression, anxiety, obsessive-compulsive disorder, and addiction. A summary of preliminary clinical trials utilizing psilocybin in each disorder is presented, along with an analysis of the neurobiological mechanisms...
Abstract The ‘‘psychedelic renaissance’’ is generating new evidence for psychedelics’ potential to treat numerous mental and substance use disorders. In particular, the United States Food and Drug Administration is poised to approve psychedelic drugs 3,4 methylenedioxymethamphetamine (MDMA) and psilocybin for the use in psychedelic-assisted therapy (PAT). Th...
Nicotine dependence is a reversible risk factor of numerous oral cavity diseases. Dentist should be non-smoking and have knowledge on diagnosis and treatment of nicotine addiction.The aim of this survey is the assessment of prevalence of nicotine dependence among Polish dentists, factors associated with this addiction and knowledge on minimal anti-nicotine i...
Abstract The recently published Imperial College study of a Phase II, double-blind, randomized, controlled trial comparing psilocybin-assisted therapy to a six-week titration of escitalopram for Major Depressive Disorder (MDD) should raise concerns for this illness category as a target of early psychedelic research given a goal of FDA approval. There are thr...
Psychedelics (i.e., ketamine, methylenedioxymethamphetamine, psilocybin) have been effectively used globally for centuries to treat mental health and addiction issues. However, in the 1950s-1970s, a number of factors, including misuse, abuse, and poorly conceptualized and conducted clinical trials, caused the Federal Drug Administration to classify most of t...
